Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DF 1001

Next Previous
Drug Profile

DF 1001

Alternative Names: DF 1001

Latest Information Update: 23 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dragonfly Therapeutics
  • Developer Dragonfly Therapeutics; Gilead Sciences
  • Class Antineoplastics; Immunotherapies; Natural killer cell therapies
  • Mechanism of Action Immunologic cytotoxicity; Immunostimulants; Natural killer cell stimulants; Natural killer T cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Oesophageal cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Solid tumours
  • Preclinical Breast cancer; Non-small cell lung cancer

Most Recent Events

  • 10 Dec 2024 Pharmacodynamics and adverse events data from a preclinical trial in Solid tumours presented at the 47th Annual San Antonio Breast Cancer Symposium (SABCS-2024)
  • 15 Feb 2024 Dragonfly Therapeutics and Gilead agree to co-develop the combination of DF1001 and Trodelvy for Breast cancer and Non small cell lung cancer
  • 15 Feb 2024 Preclinical trials in Breast cancer in USA (Parenteral) before February 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top